Healthcare / Medical Instruments & SuppliesTaipei Exchange
$82.70
-0.60 (-0.72%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-810.9M · quality 76.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-45.3%
↓Gross Margin
14.0%
↓Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.0%
FCF CAGR
—
FCF margin
-154.0%
FCF / Net income
0.97x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $419.4M · net income $-668.1M · FCF $-646.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $419.4M | $419.4M | $292.8M | $196.3M | $298.3M |
| Net Income | $-668.1M | $-668.1M | $-805.5M | $-1.20B | $-433.8M |
| EBITDA | $-608.6M | $-608.6M | $-754.4M | $-1.13B | $-370.1M |
| EPS | — | — | -8.74 | -13.09 | -4.66 |
| Gross Margin | 14.0% | 14.0% | 28.5% | 7.3% | 62.6% |
| Operating Margin | -172.2% | -172.2% | -297.9% | -427.5% | -163.5% |
| Net Margin | -159.3% | -159.3% | -275.1% | -613.8% | -145.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.08 | 0.08 | 0.11 | 0.08 | 0.06 |
| Current Ratio | 8.21 | 8.21 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-646.0M | $-646.0M | $-907.4M | $-810.9M | $-602.1M |
| Returns | |||||
| ROE | -45.3% | -45.3% | -53.0% | -51.9% | -12.1% |
| Valuation | |||||
| P/B | 5.43 | 5.43 | 2.39 | 1.82 | 1.41 |
| Growth & Yield | |||||
| Revenue Growth | 43.2% | 43.2% | 49.2% | -34.2% | — |
| EPS Growth | — | — | 33.2% | -180.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-8.74 → n/d
Residual
-7.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.